← back to search

Andrea L. Schaffer

University of Oxford · GB
Area of research
Public Health, Environmental and Occupational Health · Oncology
Research interest
Research interests include Opioid Use Disorder Treatment, COVID-19 and healthcare impacts, Pharmaceutical Practices and Patient Outcomes, and Medication Adherence and Compliance.
h-index
23
citations
3,004
works
139
NIH funding
primary concept
email

Recent publications

Time trends in newly recorded diagnoses of 19 long term conditions before, during, and after the covid-19 pandemic: population based cohort study in England using OpenSAFELY
BMJ 2026cited by 4position: middledoi
Outpatient hospital attendances in people with rheumatoid arthritis during the COVID-19 pandemic and beyond: a cohort study in three nations of the UK
Lara D. Veeken 2025cited by 0position: middledoi
Impact of long COVID on health-related quality-of-life: an OpenSAFELY population cohort study using patient-reported outcome measures (OpenPROMPT)
The Lancet Regional Health - Europe 2024cited by 94position: middledoi
Clinical coding of long COVID in primary care 2020–2023 in a cohort of 19 million adults: an OpenSAFELY analysis
EClinicalMedicine 2024cited by 23position: middledoi
OpenSAFELY: The impact of COVID‐19 on azathioprine, leflunomide and methotrexate monitoring, and factors associated with change in monitoring rate
British Journal of Clinical Pharmacology 2024cited by 2position: middledoi
Changes in sick notes associated with COVID-19 from 2020 to 2022: a cohort study in 24 million primary care patients in OpenSAFELY-TPP
BMJ Open 2024cited by 2position: firstdoi
Comparative effectiveness of nirmatrelvir/ritonavir versus sotrovimab and molnupiravir for preventing severe COVID-19 outcomes in non-hospitalised high-risk patients during Omicron waves: observational cohort study using the OpenSAFELY platform
The Lancet Regional Health - Europe 2023cited by 21position: middledoi
Five-Year Trajectories of Prescription Opioid Use
JAMA Network Open 2023cited by 17position: middledoi
Interrupted time series analysis using autoregressive integrated moving average (ARIMA) models: a guide for evaluating large-scale health interventions
BMC Medical Research Methodology 2021cited by 741position: firstdoi
Changes in antibiotic prescribing following COVID‐19 restrictions: Lessons for post‐pandemic antibiotic stewardship
British Journal of Clinical Pharmacology 2021cited by 62position: middledoi
Prevalence trends and individual patterns of antiepileptic drug use in pregnancy 2006‐2016: A study in the five Nordic countries, United States, and Australia
Pharmacoepidemiology and Drug Safety 2020cited by 56position: middledoi
Antipsychotic drug use in pregnancy: A multinational study from ten countries
Schizophrenia Research 2020cited by 53position: middledoi
Adherence to Antiretroviral Regimens in Australia: A Nationwide Cohort Study
AIDS Patient Care and STDs 2020cited by 38position: middledoi
Diagnostic and health service pathways to diagnosis of cancer-registry notified cancer of unknown primary site (CUP)
PLoS ONE 2020cited by 8position: firstdoi
Codeine use and harms in Australia: evaluating the effects of re‐scheduling
Addiction 2019cited by 59position: middledoi
Demographic, social and lifestyle risk factors for cancer registry-notified cancer of unknown primary site (CUP)
Cancer Epidemiology 2019cited by 29position: middledoi
Health-related predictors of cancer registry-notified cancer of unknown primary site (CUP)
Cancer Epidemiology 2019cited by 8position: middledoi
Rising pregabalin use and misuse in Australia: trends in utilization and intentional poisonings
Addiction 2018cited by 109position: middledoi
The crux of the matter: Did the ABC's Catalyst program change statin use in Australia?
The Medical Journal of Australia 2015cited by 65position: firstdoi
Compliance and persistence to oral bisphosphonate therapy following initiation within a secondary fracture prevention program: a randomised controlled trial of specialist vs. non-specialist management
Osteoporosis International 2014cited by 57position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Timothy Dobbins · UNSW Sydney6 papers (2015–2023)Sallie‐Anne Pearson · University of Sydney4 papers (2019–2023)Seb Bacon · Science Oxford3 papers (2023–2024)Claire M. Vajdic · UNSW Sydney3 papers (2019–2020)Joel Rhee · The University of Sydney3 papers (2019–2020)Nicholas A. Buckley · The University of Sydney3 papers (2015–2019)Oscar Perez‐Concha · UNSW Sydney3 papers (2019–2020)Ben Goldacre · Angkor Hospital for Children3 papers (2023–2024)Maarit A. Laaksonen · The University of Sydney3 papers (2019–2020)Robyn L. Ward · The University of Sydney3 papers (2019–2020)Helga Zoëga · University of Iceland3 papers (2020–2021)Chris Bates · Texas Public Policy Foundation3 papers (2023–2024) · 3 papers (2019–2020)Marina T. van Leeuwen · UNSW Sydney3 papers (2019–2020)Frank Hester · King's College Hospital2 papers (2023–2024)Jonathan Cockburn · WPP (United Kingdom)2 papers (2023–2024)Krista F. Huybrechts · Harvard University2 papers (2020–2020)Yongfu Yu · Fudan University2 papers (2020–2020)Amir Mehrkar · University of Oxford2 papers (2023–2024)Rose Cairns · The University of Sydney2 papers (2018–2019)